853297-42-4Relevant articles and documents
Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8
Bergeron, Philippe,Koehler, Michael F. T.,Blackwood, Elizabeth M.,Bowman, Krista,Clark, Kevin,Firestein, Ron,Kiefer, James R.,Maskos, Klaus,McCleland, Mark L.,Orren, Linda,Ramaswamy, Sreemathy,Salphati, Laurent,Schmidt, Steve,Schneider, Elisabeth V.,Wu, Jiansheng,Beresini, Maureen
, p. 595 - 600 (2016/07/06)
Using Sorafenib as a starting point, a series of potent and selective inhibitors of CDK8 was developed. When cocrystallized with CDK8 and cyclin C, these compounds exhibit a Type-II (DMG-out) binding mode.